Fluidigm Corporation: Investment Opportunity

Jan. 26, 2022 1:24 PM ETStandard BioTools Inc. (LAB)6 Comments
Nathan Aisenstadt profile picture
Nathan Aisenstadt


  • According to preliminary results, the company's revenue amounted to $38.2 million in the 4th quarter, up 36.4% from the previous quarter.
  • Sales of CyTOF XT introduced to the scientific community in the first half of 2021 showed a 133% increase in sales in Q3 2021 compared to Q2 2021.
  • 490 articles were published mentioning mass cytometry in 2021, which is 47.6% more than in 2020.
  • Partnered with Rover Labs to perform COVID-19 PCR testing at more than 200 New Jersey public schools.
  • 2 leading investment funds namely Casdin Capital and Viking Global Investors LP have invested $250 million in the company.

лаборатория. Пустые вакутнеры

alexey_ds/iStock via Getty Images

Fluidigm Corporation (NASDAQ:FLDM) is a leader in the development of equipment and diagnostic solutions in an emerging technology, namely mass cytometry. According to the company, the global cytometry market will reach $4 billion by 2025, which creates prerequisites for improving

Fluidigm revenue

Author's elaboration, based on Seeking Alpha

Mass Cytometry product and service revenue

Source: Author's elaboration, based on quarterly securities reports

Microfluids product and service revenue

Source: Author's elaboration, based on quarterly securities reports

Fluidigm net income

Source: Author's elaboration, based on Seeking Alpha

Fluidigm cash

Source: Author's elaboration, based on Seeking Alpha

Investment terms and approvals

Source: Author's elaboration, based on quarterly securities report

Focused on highest-growth cytometry market segments

Investor Presentation

Mass Cytometry

Source: Author's elaboration, based on quarterly securities reports

Mass Cytometry

Source: Author's elaboration, based on quarterly securities reports

Number of articles mentioning mass cytometry

Source: Author's elaboration, based on NIH

CyTOF XT: Affordable high-parameter cytometry

Investor Presentation

Innovation accelerates segment growth

Investor Presentation

Total number of COVID-19 nucleic acid amplification tests

Source: Author's elaboration, based on CDC

FOMC participants assessments of appropriate monetary policy

Federal Reserve Board


Source: Created by author

Enterprise value to revenue table

Source: Author's elaboration, based on Yahoo Finance

Fluidigm corporation total debt

Source: Author's elaboration, based on Seeking Alpha

10-Q report

Author's elaboration, based on 10-Q report

Fluidigm key financial indicators

Source: Created by author

Fluidigm price target

Source: Created by author

This article was written by

Nathan Aisenstadt profile picture
I am an independent research analyst focused on finding undervalued assets with above-average growth rates and developments that can dramatically improve the company's financial position. When investing, I use medium-term and long-term trading strategies that take into account psychological and behavioral variables and are able to mitigate the risks associated with macroeconomic and geopolitical instability.The main sectors of analysis are industrials, materials, crypto, and healthcare.When analyzing assets in the healthcare sector, in addition to examining their financial position, I delve into the safety and efficacy data of the company's product candidates from preclinical and clinical studies, allowing me to evaluate their commercial prospects. While the education received at the Hebrew University of Jerusalem contributes to a comprehensive and detailed analysis of biotechnological and physicochemical processes used in the production of goods in the agricultural, oil and gas, and chemical industries. As a result, it allows me to find the most promising assets in a rapidly changing market and publish meaningful articles on Seeking Alpha.My e-mail for any questions and suggestions: aisenathan@gmail.com

Disclosure: I/we have a beneficial long position in the shares of FLDM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sell securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.